Hologic 향후 성장

Future 기준 점검 2/6

Hologic (는) 각각 연간 19.8% 및 4.8% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 21.7% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 16.4% 로 예상됩니다.

핵심 정보

19.8%

이익 성장률

21.72%

EPS 성장률

Medical Equipment 이익 성장	12.7%
매출 성장률	4.8%
향후 자기자본이익률	16.42%
애널리스트 커버리지	Good
마지막 업데이트	02 Oct 2025

최근 향후 성장 업데이트

Analysts Have Made A Financial Statement On Hologic, Inc.'s (NASDAQ:HOLX) Third-Quarter Report

Aug 04

Hologic, Inc. (NASDAQ:HOLX) Just Reported, And Analysts Assigned A US$80.53 Price Target

Feb 07

Recent updates

Returns At Hologic (NASDAQ:HOLX) Appear To Be Weighed Down

Sep 13

Analysts Have Made A Financial Statement On Hologic, Inc.'s (NASDAQ:HOLX) Third-Quarter Report

Aug 04

Hologic, Inc. (NASDAQ:HOLX) Just Reported, And Analysts Assigned A US$80.53 Price Target

Feb 07

Is Hologic (NASDAQ:HOLX) A Risky Investment?

Jan 31

Hologic: Reasonably, But Not Compellingly Valued

Jan 17

Here's What To Make Of Hologic's (NASDAQ:HOLX) Decelerating Rates Of Return

Jan 13

Earnings Not Telling The Story For Hologic, Inc. (NASDAQ:HOLX)

Dec 22

Hologic, Inc.'s (NASDAQ:HOLX) Intrinsic Value Is Potentially 60% Above Its Share Price

Dec 04

When Should You Buy Hologic, Inc. (NASDAQ:HOLX)?

Nov 02

Hologic: Continued Room Amidst Bolt-On M&A Efforts

Oct 28

Hologic (NASDAQ:HOLX) Seems To Use Debt Rather Sparingly

Oct 17

Hologic Has A Lot Of Fine Qualities, But A Discount Valuation Isn't Among Them

Aug 27

Hologic: Women's Health Play Looks Healthier Itself

May 13

Hologic: Prospects For Growth As Headwinds Disappear

Feb 11

이익 및 매출 성장 예측

NasdaqGS:HOLX - 애널리스트 향후 추정치 및 과거 재무 데이터 (USD Millions)
날짜	매출	이익	자유현금흐름	영업현금흐름	평균 애널리스트 수
9/30/2028	4,749	1,006	1,160	1,185	5
9/30/2027	4,498	953	1,089	1,156	13
9/30/2026	4,269	845	1,047	1,095	18
9/30/2025	4,085	580	943	984	18
6/28/2025	4,039	557	917	1,069	N/A
3/29/2025	4,027	557	970	1,132	N/A
12/28/2024	4,039	744	1,105	1,255	N/A
9/28/2024	4,030	790	1,145	1,285	N/A
6/29/2024	3,988	702	1,015	1,177	N/A
3/30/2024	3,961	467	949	1,104	N/A
12/30/2023	3,969	515	859	1,018	N/A
9/30/2023	4,030	456	901	1,051	N/A
7/1/2023	4,038	484	832	961	N/A
4/1/2023	4,057	753	841	959	N/A
12/31/2022	4,466	990	1,696	1,815	N/A
9/24/2022	4,863	1,302	1,999	2,126	N/A
6/25/2022	5,226	1,512	2,283	2,423	N/A
3/26/2022	5,392	1,552	2,598	2,755	N/A
12/25/2021	5,494	1,716	2,068	2,245	N/A
9/25/2021	5,632	1,872	2,146	2,330	N/A
6/26/2021	5,663	2,038	2,108	2,307	N/A
3/27/2021	5,317	1,907	1,677	1,867	N/A
12/26/2020	4,536	1,384	1,263	1,433	N/A
9/26/2020	3,776	1,115	740	897	N/A
6/27/2020	3,295	497	573	702	N/A
3/28/2020	3,325	453	518	643	N/A
12/28/2019	3,387	84	536	659	N/A
9/28/2019	3,367	-204	536	650	N/A
6/29/2019	3,315	-30	520	634	N/A
3/30/2019	3,287	-11	N/A	705	N/A
12/29/2018	3,258	-419	N/A	668	N/A
9/29/2018	3,218	-111	N/A	733	N/A
6/30/2018	3,207	-79	N/A	667	N/A
3/31/2018	3,189	-132	N/A	21	N/A
12/30/2017	3,116	1,076	N/A	8	N/A
9/30/2017	3,059	756	N/A	8	N/A
7/1/2017	2,983	765	N/A	70	N/A
4/1/2017	2,894	790	N/A	729	N/A
12/31/2016	2,872	332	N/A	796	N/A
9/24/2016	2,833	331	N/A	798	N/A
6/25/2016	2,809	264	N/A	802	N/A
3/26/2016	2,785	208	N/A	797	N/A
12/26/2015	2,747	187	N/A	804	N/A
9/26/2015	2,705	132	N/A	797	N/A
6/27/2015	2,641	135	N/A	685	N/A
3/28/2015	2,580	116	N/A	601	N/A
12/27/2014	2,549	52	N/A	513	N/A

애널리스트 향후 성장 전망

수입 대 저축률: HOLX 의 연간 예상 수익 증가율(19.8%)이 saving rate(3.1%)보다 높습니다.

수익 vs 시장: HOLX 의 연간 수익(19.8%)이 US 시장(15.4%)보다 빠르게 성장할 것으로 예상됩니다.

고성장 수익: HOLX 의 수입은 증가할 것으로 예상되지만 상당히 증가하지는 않을 것입니다.

수익 대 시장: HOLX 의 수익(연간 4.8%)이 US 시장(연간 9.8%)보다 느리게 성장할 것으로 예상됩니다.

고성장 매출: HOLX 의 수익(연간 4.8%)은 연간 20%보다 느리게 증가할 것으로 예상됩니다.

주당순이익 성장 예측

향후 자기자본이익률

미래 ROE: HOLX의 자본 수익률은 3년 후 16.4%로 낮을 것으로 예상됩니다.

성장 기업 찾아보기

기업 분석 및 재무 데이터 상태

데이터	최종 업데이트 (UTC 시간)
기업 분석	2025/10/05 10:49
종가	2025/10/03 00:00
수익	2025/06/28
연간 수익	2024/09/28

데이터 소스

당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.

패키지	데이터	기간	미국 소스 예시 ^*
기업 재무제표	10년	손익계산서 현금흐름표 대차대조표	SEC 양식 10-K SEC 양식 10-Q
분석가 컨센서스 추정치	+3년	재무 예측 분석가 목표주가	분석가 리서치 보고서 Blue Matrix
시장 가격	30년	주가 배당, 분할 및 기타 조치	ICE 시장 데이터 SEC 양식 S-1
지분 구조	10년	주요 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
경영진	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발	10년	회사 공시	SEC 양식 8-K

^* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.

별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 스노우플레이크

이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 Github 페이지에서 확인할 수 있으며, 보고서 활용 방법에 대한 가이드와 Youtube 튜토리얼도 제공합니다.

Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.

산업 및 섹터 지표

산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.

분석가 소스

Hologic, Inc.는 53명의 분석가가 다루고 있습니다. 이 중 18명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.

분석가	기관
David Toung	Argus Research Company
Ishan Majumdar	Baptista Research
Charles Butler	Barclays

Hologic 향후 성장

Future 기준 점검 2/6

핵심 정보

최근 향후 성장 업데이트

Analysts Have Made A Financial Statement On Hologic, Inc.'s (NASDAQ:HOLX) Third-Quarter Report

Hologic, Inc. Provides Earnings Guidance for the Fourth Quarter Ending September 27, 2025

Price target decreased by 7.0% to US$71.16

Hologic, Inc. Provides Earnings Guidance for the Third Quarter of 2025

Hologic, Inc. (NASDAQ:HOLX) Just Reported, And Analysts Assigned A US$80.53 Price Target

Hologic, Inc. Revises Earnings Guidance for the Fiscal Year of 2025

Recent updates

Hologic, Inc. Receives FDA Clearance and Ce Mark for Automated Molecular Tests to Detect Common Causes of Infectious Gastroenteritis

Chairman notifies of intention to sell stock

Hologic Stock Soars After Blackstone, TPG Reportedly Revive Takeover Interest

Returns At Hologic (NASDAQ:HOLX) Appear To Be Weighed Down

Analysts Have Made A Financial Statement On Hologic, Inc.'s (NASDAQ:HOLX) Third-Quarter Report

Third quarter 2025 earnings: EPS in line with analyst expectations despite revenue beat

Hologic, Inc. Provides Earnings Guidance for the Fourth Quarter Ending September 27, 2025

Is Hologic, Inc. (NASDAQ:HOLX) Trading At A 38% Discount?

Hologic, Inc. to Report Q3, 2025 Results on Jul 30, 2025

The Price Is Right For Hologic, Inc. (NASDAQ:HOLX)

Hologic, Inc.(NasdaqGS:HOLX) dropped from Russell 1000 Dynamic Index

Is Hologic (NASDAQ:HOLX) Using Too Much Debt?

Investor sentiment improves as stock rises 16%

Blackstone, TPG Reportedly to Offer $16 Billion to Buy Hologic

Hologic to Present New Data at ASCO 2025 Reinforcing the Practice-Changing Role of the Breast Cancer Index®? Test in Helping to Deliver More Personalized Care to Patients

Hologic: Soft Performance, But Cheap Enough

Price target decreased by 7.0% to US$71.16

Second quarter 2025 earnings: EPS misses analyst expectations

Hologic, Inc. Provides Earnings Guidance for the Third Quarter of 2025

Hologic, Inc. to Present Pivotal New Research Conducted by A Top-Tier Healthcare Facility Focused on the AI-Driven Mammography Technology

Hologic (NASDAQ:HOLX) Has More To Do To Multiply In Value Going Forward

Hologic, Inc. Appoints Wayde Mcmillan to Its Board of Directors, Effective April 4, 2025

Hologic, Inc. to Report Q2, 2025 Results on May 01, 2025

Is Hologic, Inc. (NASDAQ:HOLX) Potentially Undervalued?

Hologic, Inc. Obtains CE Mark for Affirm® Contrast Biopsy Software

Hologic, Inc. Announces FDA Clearance of Aptima SARS-CoV-2 Assay

Hologic, Inc. (NASDAQ:HOLX) Just Reported, And Analysts Assigned A US$80.53 Price Target

Hologic, Inc. Revises Earnings Guidance for the Fiscal Year of 2025

First quarter 2025 earnings: EPS exceeds analyst expectations

Is Hologic (NASDAQ:HOLX) A Risky Investment?

Hologic, Inc., Annual General Meeting, Feb 26, 2025

Hologic: Reasonably, But Not Compellingly Valued

Hologic, Inc. Provides Earnings Guidance for the First Quarter of the Fiscal Year 2025

Here's What To Make Of Hologic's (NASDAQ:HOLX) Decelerating Rates Of Return

Hologic, Inc. Announces Director Retirement

Hologic, Inc. (NasdaqGS:HOLX) completed the acquisition of Gynesonics, Inc.

Earnings Not Telling The Story For Hologic, Inc. (NASDAQ:HOLX)

Hologic, Inc. Announces New Data to Be Presented At SABCS 2024 Investigates the Potential Role of the Breast Cancer Index Test in Identifying Patients with Minimal Risk of Distant Recurrence

Chief Operating Officer notifies of intention to sell stock

Hologic, Inc.'s (NASDAQ:HOLX) Intrinsic Value Is Potentially 60% Above Its Share Price

Hologic, Inc. to Showcase AI-Powered Breast Imaging Advancements Designed to Assess Breast Density, Enhance Workflows and Improve Cancer Detection

Hologic, Inc. Provides Earnings Guidance for the First Quarter and Fiscal Year of 2025

When Should You Buy Hologic, Inc. (NASDAQ:HOLX)?

Hologic: Continued Room Amidst Bolt-On M&A Efforts

Hologic (NASDAQ:HOLX) Seems To Use Debt Rather Sparingly

Hologic, Inc. (NasdaqGS:HOLX) agreed to acquire Gynesonics, Inc. for $350 million.

Hologic, Inc. to Report Q4, 2024 Results on Nov 04, 2024

Hologic, Inc. (NasdaqGS:HOLX) announces an Equity Buyback for $1,500 million worth of its shares.

Chief Financial Officer notifies of intention to sell stock

Hologic Has A Lot Of Fine Qualities, But A Discount Valuation Isn't Among Them

Chairman notifies of intention to sell stock

Hologic, Inc. Provides Earnings Guidance for the Fourth Quarter of 2024

Third quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Hologic, Inc. (NasdaqGS:HOLX) completed the acquisition of Endomagnetics Ltd. for approximately $310 million.

Hologic, Inc. to Report Q3, 2024 Results on Jul 29, 2024

Now 19% undervalued after recent price drop

Now 20% undervalued after recent price drop

Now 20% undervalued after recent price drop

Now 20% undervalued after recent price drop

Hologic: Women's Health Play Looks Healthier Itself

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Hologic, Inc. Reports Impairment of Intangible Assets for the Second Quarter Ended March 30, 2024

Hologic, Inc. (NasdaqGS:HOLX) signed a definitive agreement to acquire Endomagnetics Ltd. for approximately $310 million.

Now 20% undervalued

Hologic, Inc. to Report Q2, 2024 Results on May 02, 2024

Independent Director notifies of intention to sell stock

Now 20% undervalued

Hologic, Inc. and Biotheranostics, Inc. Announces Newly Published Study Results Reveal That Use of the Breast Cancer Index®? Test

Now 20% undervalued